Recent News

By Category: Countermeasures

Early Tests Bode Well for Bioterrorism Treatment

(Nextgov) A potential drug for use against Marburg virus has been shown in initial testing to be safe for humans, the Boston Business Journal reported. Pharmaceutical firm Sarepta Therapeutics announced that when the treatment was given in various dosage amounts over two weeks to 40 volunteers in a Phase 1 study, the drug was discerned Read More »

February 14, 2014
| Filed under North America, Bioterrorism, Countermeasures, and Research
Share

Uganda: CDC Health Projects Improve Disease Detection and Control

(All Africa) The US Centres for Disease Control and Prevention (CDC) global health security (GHS) projects on early disease detection, response and prevention in Uganda and Vietnam have resulted in improvements in those areas. This was revealed in an article published in the Morbidity and Mortality Weekly Report released by CDC on January 30. For Read More »

February 12, 2014
| Filed under Africa, Asia/Pacific, North America, Agents & Toxins, Biosafety, Countermeasures, and International
Share

Sarepta’s bioterrorism drug found safe in humans

(Boston Business Journal) While most attention on Sarepta Therapeutics has concerned its drugs for Duchenne’s muscular dystrophy, today the Cambridge biotech reported data from an early-stage trial of its potential drug for the bio-terrorism infection known as the Marburg virus. Marburg is a deadly infection disease first recognized in 1967 and endemic to Africa. Its Read More »

February 12, 2014
| Filed under North America, Bioterrorism, Countermeasures, and Research
Share

House Approves Bill on WMD Medical Countermeasures Expenditures

(Global Security Newswire-NTI) The U.S. House on Monday passed a bill that would authorize the use of certain federal grants for improving medical responses to a chemical or biological strike. “Experts have repeatedly noted that the threat of a WMD attack is real,” said Representative Gus Bilirakis (R-Fla.), the bill sponsor, in released comments.”

February 11, 2014
| Filed under Bioterrorism, Countermeasures, and Policy & Initiatives
Share

HHS Taps Rempex for Biothreat, Antimicrobial Defense Drug

(HHS) The Department of Health and Human Services will invest up to $90 million over five years in a partnership with Rempex Pharmaceuticals to further develop an experimental drug against biothreat pathogens and drug-resistant bacteria. HHS’ Biomedical Advanced Research and Development Authority will initially put forth $19.8 million to support Rempex’s research and development of Read More »